Ghana has made history by becoming the first country in Africa to approve a new malaria vaccine, marking a significant milestone in the fight against the disease that claims hundreds of thousands of lives each year, especially in Sub-Saharan Africa.
The vaccine, known as R21, was developed by Oxford University in collaboration with the Serum Institute of India and has been approved for domestic use by Ghana’s Food and Drugs Authority (FDA) for children aged 5 months to 36 months, the age group most vulnerable to malaria.
Malaria is a mosquito-borne disease that is responsible for over 600,000 deaths annually, with most of the deaths occurring in Sub-Saharan Africa. In Ghana, malaria is the leading cause of morbidity and mortality, with an estimated 20% of all hospital admissions and 30% of all outpatient cases attributed to the disease. With over 5.5 million cases recorded in Ghana in 2020 alone, the approval of the malaria vaccine is a significant step in the fight against the disease.
The R21 vaccine is the second malaria vaccine to be approved in recent years and is expected to provide significant protection against the disease. The vaccine has shown promising results in clinical trials, with an efficacy rate of up to 77%, and works by triggering the immune system to attack the malaria parasite when it enters the bloodstream, preventing the parasite from multiplying and causing illness.
The approval of the vaccine by the Ghanaian FDA is unusual as it comes before the publication of final-stage trial data. However, experts believe that this move is a testament to the country’s commitment to tackling malaria and improving public health outcomes.
Ghana’s regulators have taken a proactive stance in the wake of the COVID-19 pandemic, ensuring that they are not left behind in the race to secure life-saving vaccines. The approval of the malaria vaccine in Ghana is expected to have a significant impact on the country’s health outcomes, particularly for children and pregnant women, who are at a higher risk of contracting malaria in the country.
Despite the vaccine still needing to be assessed by the World Health Organization (WHO) and other regulatory bodies before it can be rolled out in other countries, the approval of the vaccine in Ghana is a significant step towards the WHO’s goal of eradicating malaria globally. The WHO has set a target of reducing malaria cases by at least 90% by 2030, and the approval of the R21 vaccine is a significant step towards achieving that goal in Ghana.
The Ghanaian government has announced that it will work with the Ghana Malaria Programme and the country’s immunization body, the Expanded Programme on Immunization (EPI), to roll out the vaccine to children in the country. However, the timeline for the rollout is yet to be announced, as other regulatory bodies continue to assess the vaccine’s safety and efficacy.
In addition to the approval of the vaccine, Ghana is also making progress in other areas related to malaria control. The country is one of the first in Africa to adopt the use of a new mosquito net that is treated with a long-lasting insecticide, which is a significant step towards reducing malaria cases in the country. However, there is still a need for increased investment in healthcare infrastructure and research into new treatments for malaria to further advance the fight against the disease in Ghana and other countries in Sub-Saharan Africa.
The approval of the malaria vaccine in Ghana is a significant step forward in the fight against the deadly disease, particularly in Sub-Saharan Africa. With the approval of the vaccine, Ghana is leading the way in the fight against malaria in Ghana, and this could serve as an inspiration for other countries to follow suit.
Image Credit: Julia Koblitz on Unsplash
